Logo image of MRVI

MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis

NASDAQ:MRVI - Nasdaq - US56600D1072 - Common Stock - Currency: USD

2.095  +0.17 (+8.55%)

Fundamental Rating

2

Overall MRVI gets a fundamental rating of 2 out of 10. We evaluated MRVI against 55 industry peers in the Life Sciences Tools & Services industry. While MRVI seems to be doing ok healthwise, there are quite some concerns on its profitability. MRVI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MRVI has reported negative net income.
MRVI had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MRVI reported negative net income in multiple years.
In the past 5 years MRVI always reported a positive cash flow from operatings.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

With a Return On Assets value of -14.37%, MRVI perfoms like the industry average, outperforming 49.09% of the companies in the same industry.
MRVI has a Return On Equity of -44.53%. This is in the lower half of the industry: MRVI underperforms 67.27% of its industry peers.
Industry RankSector Rank
ROA -14.37%
ROE -44.53%
ROIC N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

With a Gross Margin value of 41.79%, MRVI perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
MRVI's Gross Margin has declined in the last couple of years.
MRVI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRVI has more shares outstanding
Compared to 5 years ago, MRVI has less shares outstanding
The debt/assets ratio for MRVI has been reduced compared to a year ago.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

MRVI has an Altman-Z score of 1.10. This is a bad value and indicates that MRVI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MRVI (1.10) is comparable to the rest of the industry.
MRVI has a Debt/Equity ratio of 0.99. This is a neutral value indicating MRVI is somewhat dependend on debt financing.
The Debt to Equity ratio of MRVI (0.99) is worse than 78.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Altman-Z 1.1
ROIC/WACCN/A
WACC12.18%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 7.53 indicates that MRVI has no problem at all paying its short term obligations.
The Current ratio of MRVI (7.53) is better than 85.45% of its industry peers.
A Quick Ratio of 6.65 indicates that MRVI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.65, MRVI belongs to the top of the industry, outperforming 85.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 6.65
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MRVI have decreased strongly by -433.33% in the last year.
Looking at the last year, MRVI shows a very negative growth in Revenue. The Revenue has decreased by -10.30% in the last year.
MRVI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.61% yearly.
EPS 1Y (TTM)-433.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)-10.3%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-23.72%

3.2 Future

MRVI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.07% yearly.
MRVI is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -6.80% yearly.
EPS Next Y-160.82%
EPS Next 2Y-38.65%
EPS Next 3Y-8.23%
EPS Next 5Y-21.07%
Revenue Next Year-25.88%
Revenue Next 2Y-7.99%
Revenue Next 3Y0.89%
Revenue Next 5Y-6.8%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A cheap valuation may be justified as MRVI's earnings are expected to decrease with -8.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.65%
EPS Next 3Y-8.23%

More info and screens

0

5. Dividend

5.1 Amount

MRVI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (4/23/2025, 1:00:01 PM)

2.095

+0.17 (+8.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners85.89%
Inst Owner Change0.27%
Ins Owners1.09%
Ins Owner Change49.6%
Market Cap532.84M
Analysts74
Price Target6 (186.4%)
Short Float %7.36%
Short Ratio2.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-101.02%
Min EPS beat(2)-154.98%
Max EPS beat(2)-47.06%
EPS beat(4)1
Avg EPS beat(4)-69.76%
Min EPS beat(4)-154.98%
Max EPS beat(4)22.99%
EPS beat(8)2
Avg EPS beat(8)-58.64%
EPS beat(12)6
Avg EPS beat(12)-35.14%
EPS beat(16)10
Avg EPS beat(16)-20.25%
Revenue beat(2)0
Avg Revenue beat(2)-4.34%
Min Revenue beat(2)-5.38%
Max Revenue beat(2)-3.3%
Revenue beat(4)2
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)3.92%
Revenue beat(8)3
Avg Revenue beat(8)-1.55%
Revenue beat(12)5
Avg Revenue beat(12)-1.1%
Revenue beat(16)8
Avg Revenue beat(16)0.53%
PT rev (1m)-32.75%
PT rev (3m)-35.17%
EPS NQ rev (1m)-231.62%
EPS NQ rev (3m)-214.25%
EPS NY rev (1m)-291.41%
EPS NY rev (3m)-397.2%
Revenue NQ rev (1m)-30.24%
Revenue NQ rev (3m)-32.03%
Revenue NY rev (1m)-26.91%
Revenue NY rev (3m)-27.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.06
P/FCF N/A
P/OCF 71.38
P/B 1.64
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)0.03
OCFY1.4%
SpS1.02
BVpS1.28
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.37%
ROE -44.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.79%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score5
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.4%
Cap/Sales 12.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 6.65
Altman-Z 1.1
F-Score5
WACC12.18%
ROIC/WACCN/A
Cap/Depr(3y)93.62%
Cap/Depr(5y)87.93%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-433.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-160.82%
EPS Next 2Y-38.65%
EPS Next 3Y-8.23%
EPS Next 5Y-21.07%
Revenue 1Y (TTM)-10.3%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-23.72%
Revenue Next Year-25.88%
Revenue Next 2Y-7.99%
Revenue Next 3Y0.89%
Revenue Next 5Y-6.8%
EBIT growth 1Y-180.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-369.91%
EBIT Next 3Y182.16%
EBIT Next 5Y83.02%
FCF growth 1Y-139.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.09%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%